NCT01586195View on ClinicalTrials.gov

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

PHASE2TerminatedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Malignant Melanoma
Interventions
DRUG

Vemurafenib

Vemurafenib 960 mg BID

Trial Locations (15)

10032

Columbia University Medical Center, New York

15232

UPCI Cancer Institute; Cancer Pavillion, Pittsburgh

30308

Emory University; Winship Cancer Institute, Atlanta

33612

Moffitt Cancer Center, Tampa

37232

Vanderbilt Univ Medical Ctr, Nashville

43219

Mid Ohio Onc Hematology Inc, Columbus

60068

Oncology Specialists, S.C., Park Ridge

63110

Washington University School of Medicine, St Louis

75246

Texas Oncology-Baylor Sammons Cancer Center, Dallas

80045

University of Colorado; Anschutz Cancer Pavilion, Aurora

85724

Arizona Cancer Center, Tucson

90025

The Angeles Clinic and Research Institute, Santa Monica Office, Santa Monica

90095

UCLA School of Medicine; Hematology/Oncology, Los Angeles

92093

UCSD Moores Cancer Center, La Jolla

07960

Atlantic Health System, Morristown

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT01586195 - Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E | Biotech Hunter | Biotech Hunter